There are currently 8 active clinical trials seeking participants for Ocular Hypertension research studies. The states with the highest number of trials for Ocular Hypertension participants are California, Texas, Florida and Georgia.
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
NCT06689696
Recruiting
The goal of this clinical trial is to learn if a new contact lens device can record patterns in eye pressure for 24 hours in adults with glaucoma and in healthy participants. The main questions it aims to answer are: * Is the contact lens device able to detect patterns in eye pressure that happens naturally between nighttime and daytime? * Are the contact lens recording patterns similar when repeated one week later? * What eye problems do participants have when wearing contact lens for up to 2... Read More
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
04/15/2025
Locations: Nvision Clinical Reseacrh, LLC, Fullerton, California +2 locations
Conditions: Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
Register for Updates
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Walman Eye Center /ID# 252153, Sun City, Arizona +44 locations
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Next Generation Rocklatan
NCT06441643
Recruiting
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Orange County Ophthalmology Medical Group, Garden Grove, California +11 locations
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
NCT06267274
Recruiting
A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: West Coast Eye Institute, Bakersfield, California +3 locations
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
NCT06152861
Recruiting
The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Glaukos Clinical Study Site, Newport Beach, California
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
NCT05273385
Recruiting
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Glaucoma, Ocular Hypertension, Open Angle Glaucoma
Register for Updates
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357
Recruiting
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2022
Locations: Eye Research Foundation Inc., Newport Beach, California +8 locations
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates
Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension
NCT05277870
Recruiting
The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2022
Locations: University of Washington, Seattle, Washington
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates